DOCSLIB.ORG

ICRS2017 Symposium Final Programme

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
ICRS2017 Symposium Final Programme TH 27 ANNUAL SYMPOSIUM OF THE INTERNATIONAL CANNABINOID RESEARCH SOCIETY MONTRÉAL, QC CANADA JUNE 22 - 27, 2017 TH 27 ANNUAL SYMPOSIUM OF THE INTERNATIONAL CANNABINOID RESEARCH SOCIETY MONTRÉAL JUNE 22 – 27, 2017 Symposium Programming by Cortical Systematics LLC Copyright © 2017 International Cannabinoid Research Society Research Triangle Park, NC USA ISBN: 978-0-9892885-6-9 These abstracts may be cited in the scientific literature as follows: Author(s), Abstract Title (2017) 27th Annual Symposium on the Cannabinoids, International Cannabinoid Research Society, Research Triangle Park, NC, USA, Page #. Funding for this conference was made possible in part by grant 2R13DA016280 from the National Institute on Drug Abuse. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S. Government. ICRS Sponsors Government Sponsors National Institute on Drug Abuse Non- Profit Organization Sponsors Monique and George Braude Memorial Foundation Kang Tsou Memorial Fund 2017 Symposium on the Cannabinoids Conference Coordinators Matt Hill, Ph.D. Cecilia Hillard, Ph.D. Jason Schechter, Ph.D. Programme Committee Mary Abood, Ph.D. Steve Alexander, Ph.D. Ziva Cooper, Ph.D. Meg Haney, Ph.D. Cece Hillard, Ph.D. Andrea Hohmann, Ph.D. Aron Lichtman, Ph.D. Mauro Maccarrone, Ph.D. Ian MacGregor, Ph.D. Jayme McReynolds, Ph.D. Maria Morena, Ph.D. Pal Pacher, M.D., Ph.D. Sachin Patel, M.D., Ph.D. Roger Pertwee, MA, D.Phil., D.Sc. Haley Vecchiarelli, Ph.D. Mark Ware, MBBS, MRCP Committee on Awards Steve Kinsey, Ph.D., Chair Aron Lichtman, Ph.D. Sachin Patel, M.D., Ph.D. Keith Sharkey, Ph.D. Student Prizes Committee Chair Steve Alexander, Ph.D. Mechoulam Award Committee Mary Abood, Ph.D. Francis Barth, Ph.D. Benjamin Cravatt, Ph.D. Vincenzo Di Marzo, Ph.D. Cecilia Hillard, Ph.D. Allyn Howlett, Ph.D. John Huffman, Ph.D. George Kunos, M.D., Ph.D. Gerard Le Fur, Ph.D. Aron Lichtman, Ph.D. Beat Lutz, Ph.D. Ken Mackie, M.D. Mauro Maccarrone, Ph.D. Alex Makriyannis, Ph.D. Roger Pertwee, D.Phil, D.Sc. Raj Razdan, Ph.D. Patti Reggio, Ph.D. Murielle Rinaldi- Carmona, Ph.D. 2017 ICRS Board of Directors Executive Director Cecilia Hillard, Ph.D. President Matt Hill, Ph.D. President- Elect Heather Bradshaw, Ph.D. Past President Michelle Glass, Ph.D. Secretary Sachin Patel, M.D., Ph.D. Treasurer Steve Kinsey, Ph.D. International Secretary Roger Pertwee, M.a., D.Phil, D.Sc. Student Representative Natalia Małek, M.Sc. Grant PI Jenny Wiley, Ph.D. Managing Director Jason Schechter, Ph.D. nd Registration: June 22 , 2017 (16.00 – 18.00) Le Centre Sheraton, Montréal, QC, Canada Welcome Reception: 18.30 – 20.00 4th Floor Lobby Day 1 Friday, June 23rd 7.00 Breakfast Welcome and Opening Remarks 8.30 Salle De Bal Centre & Est Oral Session 1. Inflammation and Autoimmunity CHAIRS: MELANIE KELLY AND STEVE KINSEY Jenny L. Wilkerson, DIACYLGLYCEROL LIPASE BETA KNOCKOUT MICE DISPLAY 8.45 Benjamin F. Cravatt 1 PROTECTION FROM EXPERIMENTAL and Aron H. Lichtman AUTOIMMUNE ENCEPHALOMYELITIS NEUROPROTECTION VIA CANNABINOID RECEPTOR Ian Burkovskiy, Juan 2 ACTIVATION AS MEANS 9.00 Zhou, Melanie E. Kelly 2 TO PREVENT CNS INJURY- and Christian Lehmann INDUCED IMMUNODEFICIENCY SYNDROME IN MICE Richard Porter, Anna-Maria Szcesniak, INVESTIGATING NOVEL SELECTIVE James Toguri, Simon CANNABINOID 2 RECEPTOR Gebremeskel, Brent 9.15 AGONISTS AS POTENTIAL 3 Johnston, Christian THERAPEUTIC DRUGS FOR THE Lehmann, Uwe Grether, TREATMENT OF UVEITIS Christoph Ullmer and Melanie Kelly Natalia Murataeva, A ROLE FOR CANNABINOID Sally Miller, Cecilia 9.30 CB2 RECEPTORS IN CORNEAL 4 Hillard, Julian Romero WOUND HEALING and Alex Straiker Resat Cinar, Bernadette R. Gochuico, IDENTIFYING CANNABINOID CB1 Malliga Iyer, Tadafumi RECEPTOR AS A THERAPEUTIC Yokoyama, Joshua K. TARGET FOR IDIOPATHIC 9.45 5 Park, Nathan J. Coffey, PULMONARY FIBROSIS AND A Tony Jourdan, DUAL-TARGETING PARTNER FOR William A. Gahl IMPROVING ANTI-FIBROTIC EFFICACY and George Kunos URB597 AND JZL184 PROTECTS Daniel Couch, Jon Lund 10.00 THE HUMAN COLON AGAINST 6 and Saoirse O'Sullivan INFLAMMATION VIA CB1 Haley A. Vecchiarelli, Maria Morena, Kaitlyn Tan, Catherine DYNAMIC REGULATION OF THE M. Keenan, Martin 10.15 CENTRAL ENDOCANNABINOID 7 Sticht, Kira Leitl, SYSTEM INDUCED BY COLITIS Winnie Ho, Min Qiao, Keith A. Sharkey and Matthew N. Hill 10.30 Coffee Break Oral Session 2. Drug Development and Medicinal Chemistry CHAIRS: MARY ABOOD AND MARIO VAN DER STELT Annelot C.M. van Esbroeck, Antonius P.A. Janssen, Armand B. Cognetta, Daisuke Ogasawara, Guy Shpak, Mark van der Kroeg, Vasudev Kantae, Marc P. Baggelaar, Femke M.S. de Vrij, Hui Deng, Marco Allarà, Filomena ACTIVITY-BASED Fezza, Zhanmin Lin, Tom van der PROTEIN PROFILING REVEALS Wel, Marjolein Soethoudt, Elliot 11.00 D. Mock, Hans den Dulk, Ilse L. OFF-TARGET PROTEINS OF THE 8 Baak, Bogdan I. Florea, Giel FATTY ACID AMIDE HYDROLASE Hendriks, Luciano De Petrocellis, INHIBITOR BIA 10-2474 Herman S. Overkleeft, Thomas Hankemeier, Chris I. De Zeeuw, Vincenzo Di Marzo, Mauro Maccarrone, Benjamin F. Cravatt, Steven A. Kushner and Mario van der Stelt Richard C. Kevin, POTENTIALLY TOXIC THERMOLYTIC Alexander L. Kovach, 11.15 DEGRADANTS OF CARBOXAMIDE 9 Iain S. McGregor SYNTHETIC CANNABINOIDS and Brian F. Thomas Alessia Ligresti, SURPRISING MECHANISM David Woodward, OF FAAH INHIBITION 11.30 Jose Martos, Sabatino 10 BY NEWLY DESIGNED Maione, Gennaro Marino MULTI-TARGET ANALGESICS and Vincenzo Di Marzo Sergiy Tyukhtenko, Girija Rajarshi, Xiaoyu Ma, Ioannis THE DISCOVERY OF Karageorgos, Nikolai ALLOSTERIC SITES OF HUMAN Zvonok, Elyssia S. 11.45 MONOACYLGLYCEROL LIPASE 11 Gallagher, Hongwei FOR IDENTIFICATION OF NOVEL Huang, Kiran Vemuri, PHARMACEUTICALS Jeffrey W. Hudgens, Spiro Pavlopoulos and Alexandros Makriyannis 12.00 Lunch Poster Session 1 13.00 - 15.00 P1 Salle De Bal Ouest Young Investigator Award Presentation CARDIOVASCULAR EFFECTS OF CANNABIDIOL 15.00 Saoirse O’Sullivan Associate Professor, Faculty of Medicine and Health Sciences University of Nottingham United Kingdom Oral Session 3. Endocannabinoids, Related Lipids and Cannabinoid Receptors CHAIRS: HEATHER BRADSHAW AND RUTH ROSS Diane L. Lynch, CRYSTAL PACKING ISSUES IN 15.30 Dow P. Hurst and 12 THE CB1 CRYSTAL STRUCTURES Patricia H. Reggio Attila Oláh, Majid A. Alam, CB1 REGULATES Gréta Kis, Zoltán Hegyi, MITOCHONDRIAL FUNCTIONS 15.45 Johannes Lerchner, OF HUMAN EPIDERMAL 13 Silvia Vidali, Andreas KERATINOCYTES IN SITU Zimmer, Tamás Bíró AND IN VITRO and Ralf Paus Amey Dhopeshwarkar, 1-ARACHIDONOYLGLYCEROL Zachary Osborne, 16.00 SIGNALING AT CANNABINOID 14 Alex Straiker CB1 RECEPTORS and Ken Mackie Emma Leishman, REGION AND DEVELOPMENT- Michelle Murphy, DEPENDENT EFFECTS OF CP 55,940 16.15 15 Ken Mackie ON THE WIDER ENDOCANNABINOID and Heather B Bradshaw LIPIDOME IN THE MOUSE BRAIN Jennifer Bialecki, Alexander W. Lohman, PANNEXIN-1 TRANSPORTS Nicholas L. Weilinger, ANANDAMIDE RESULTING 16.30 16 Haley A. Vecchiarelli, IN MODULATION OF GABA Matthew N. Hill TRANSMISSION and Roger J. Thompson 16.45 Coffee Break Linda Console-Bram, Sandra M Ciuciu, MODULATION OF THE ENDOGENOUS Pingwei Zhao, 17.15 CANNABINOID SYSTEM BY NAGLY 17 Robert E. Zipkin, VIA GPR18 AND GPR55 Eugen Brailiou and Mary E. Abood Gregory Carbonetti, TRANSPORT OF MAGL-PRODUCED Xiaoxue Peng, LIPIDS BY FABP5 LEADS TO 17.30 Tessa Wilpshaar, 18 INCREASED PROSTATE Simon D’Oelsnitz, CANCER AGGRESSION and Martin Kaczocha Fabiana Piscitelli, Giulia Donvito, Pretal Muldoon, Asti Jackson, Rosa Maria Vitale, Enrico D'Aniello, Catia Giordano, Bogna M. Ignatowska- OLEOYLGLYCINE IS PRODUCED Jankowska, Mohammed BY BRAIN TRAUMA AS A 17.45 A. Mustafa, Gavin N. 19 NOVEL AND MULTI-TARGET Petrie, Linda Parker, Reem Smoum, ENDOGENOUS LIPID SIGNAL Sabatino Maione, Aron H. Lichtman, M. Imad Damaj, Vincenzo Di Marzo and Raphael Mechoulam Presidential Plenary Speaker ACCOMPLICES TO MURDER: ENDOCANNABINOIDS DIRECT MICROGLIA TO KILL NEWBORN NEURONS 18.00 Margaret McCarthy, Ph.D. Professor and Chair DepartMent of PharMacology School of Medicine University of Maryland United States Notes: Day 2 Saturday, June 24th 7.00 Breakfast Oral Session 4. Pain CHAIRS: ANDREA HOHMANN AND ARON LICHTMAN Alex Hanson, ENDOCANNABINOID-MEDIATED 8.30 Emily Kabeiseman HABITUATION PERSISTENTLY 20 and Brian Burrell REDUCES NOCICEPTIVE SIGNALING Matthew Elmes, Joseph Sweeney, Olivia Joseph, TOWARDS A NEW CLASS Gregory Carbonetti, OF ANTINOCICEPTIVE DRUG: Simon Tong, Su Yan, DEVELOPMENT OF FATTY 8.45 Kongzhen Hu, 21 ACID BINDING PROTEIN Hao-Chi Hsu, Huilin Li, INHIBITORS TO ALTER THE Robert Rizzo, ENDOCANNABINOID TONE Iwao Ojima, Martin Kaczocha and Dale Deutsch INFLAMMATORY PAIN CHANGES Adrianne R. Wilson- THE EXPRESSION AND FUNCTION 9.00 Poe, Chris Trousdale 22 OF CB1 RECEPTORS IN THE and Jose Morón PERIAQUEDUCTAL GRAY Caitlin Nealon, Angela Henderson-Redmond, AGONIST-SPECIFIC MECHANISMS 9.15 Rebecca LaFleur, OF CANNABINOID TOLERANCE IN 23 Matt Yuill DESENSITIZATION RESISTANT MICE and Daniel Morgan Rebecca M. Craft, CANNABIDIOL MODULATION 9.30 Nicholas Z. Greene OF ANTINOCICEPTIVE 24 and Jenny L. Wiley TOLERANCE TO THC BRAIN PERMEANT AND IMPERMEANT INHIBITORS OF FATTY-ACID AMIDE HYDROLASE SUPPRESS THE Richard A. Slivicki and DEVELOPMENT AND MAINTENANCE 9.45 25 Andrea G. Hohmann OF PACLITAXEL-INDUCED NEUROPATHIC PAIN AND SYNERGIZE WITH THE OPIOID ANALGESIC MORPHINE Zachary A. Curry, MONOACYLGLYCEROL
Load more

Recommended publications
  • Cannabidiol Attenuates Seizures and Social Deficits in a Mouse Model of Dravet Syndrome
    Cannabidiol attenuates seizures and social deficits in a mouse model of Dravet syndrome Joshua S. Kaplana, Nephi Stellaa,b,1, William A. Catteralla,1,2, and Ruth E. Westenbroeka,1 aDepartment of Pharmacology, University of Washington, Seattle, WA 98195; and bDepartment of Psychiatry and Behavioral Sciences, University of Washington, Seattle, WA 98195 Contributed by William A. Catterall, September 7, 2017 (sent for review July 3, 2017; reviewed by Lori L. Isom, Daniele Piomelli, and Peter C. Ruben) Worldwide medicinal use of cannabis is rapidly escalating, despite 17). Previous work showed that DS symptoms result from the loss- limited evidence of its efficacy from preclinical and clinical studies. of-function of Nav1.1 channels, which selectively reduces sodium Here we show that cannabidiol (CBD) effectively reduced seizures current and excitatory drive in many types of GABAergic inter- and autistic-like social deficits in a well-validated mouse genetic neurons (13, 14, 18–20). Accordingly, targeting the Scn1a mutation model of Dravet syndrome (DS), a severe childhood epilepsy disorder to Nav1.1 channels in forebrain GABAergic interneurons re- caused by loss-of-function mutations in the brain voltage-gated capitulated the DS phenotype and established that hypoexcitability sodium channel NaV1.1. The duration and severity of thermally in- of these interneurons is sufficient to cause the epileptic phenotype duced seizures and the frequency of spontaneous seizures were sub- (21) and autistic-like behaviors (16) observed in DS mice. In con- stantially decreased. Treatment with lower doses of CBD also trast, targeting the Scn1a mutation to excitatory neurons ameliorates improved autistic-like social interaction deficits in DS mice.
    [Show full text]
  • Cannabinoids and Endocannabinoid System Changes in Intestinal Inflammation and Colorectal Cancer
    cancers Review Cannabinoids and Endocannabinoid System Changes in Intestinal Inflammation and Colorectal Cancer Viktoriia Cherkasova, Olga Kovalchuk * and Igor Kovalchuk * Department of Biological Sciences, University of Lethbridge, Lethbridge, AB T1K 7X8, Canada; [email protected] * Correspondence: [email protected] (O.K.); [email protected] (I.K.) Simple Summary: In recent years, multiple preclinical studies have shown that changes in endo- cannabinoid system signaling may have various effects on intestinal inflammation and colorectal cancer. However, not all tumors can respond to cannabinoid therapy in the same manner. Given that colorectal cancer is a heterogeneous disease with different genomic landscapes, experiments with cannabinoids should involve different molecular subtypes, emerging mutations, and various stages of the disease. We hope that this review can help researchers form a comprehensive understanding of cannabinoid interactions in colorectal cancer and intestinal bowel diseases. We believe that selecting a particular experimental model based on the disease’s genetic landscape is a crucial step in the drug discovery, which eventually may tremendously benefit patient’s treatment outcomes and bring us one step closer to individualized medicine. Abstract: Despite the multiple preventive measures and treatment options, colorectal cancer holds a significant place in the world’s disease and mortality rates. The development of novel therapy is in Citation: Cherkasova, V.; Kovalchuk, critical need, and based on recent experimental data, cannabinoids could become excellent candidates. O.; Kovalchuk, I. Cannabinoids and This review covered known experimental studies regarding the effects of cannabinoids on intestinal Endocannabinoid System Changes in inflammation and colorectal cancer. In our opinion, because colorectal cancer is a heterogeneous Intestinal Inflammation and disease with different genomic landscapes, the choice of cannabinoids for tumor prevention and Colorectal Cancer.
    [Show full text]
  • Modifications to the Harmonized Tariff Schedule of the United States to Implement Changes to the Pharmaceutical Appendix
    United States International Trade Commission Modifications to the Harmonized Tariff Schedule of the United States to Implement Changes to the Pharmaceutical Appendix USITC Publication 4208 December 2010 U.S. International Trade Commission COMMISSIONERS Deanna Tanner Okun, Chairman Irving A. Williamson, Vice Chairman Charlotte R. Lane Daniel R. Pearson Shara L. Aranoff Dean A. Pinkert Address all communications to Secretary to the Commission United States International Trade Commission Washington, DC 20436 U.S. International Trade Commission Washington, DC 20436 www.usitc.gov Modifications to the Harmonized Tariff Schedule of the United States to Implement Changes to the Pharmaceutical Appendix Publication 4208 December 2010 (This page is intentionally blank) Pursuant to the letter of request from the United States Trade Representative of December 15, 2010, set forth at the end of this publication, and pursuant to section 1207(a) of the Omnibus Trade and Competitiveness Act, the United States International Trade Commission is publishing the following modifications to the Harmonized Tariff Schedule of the United States (HTS) to implement changes to the Pharmaceutical Appendix, effective on January 1, 2011. Table 1 International Nonproprietary Name (INN) products proposed for addition to the Pharmaceutical Appendix to the Harmonized Tariff Schedule INN CAS Number Abagovomab 792921-10-9 Aclidinium Bromide 320345-99-1 Aderbasib 791828-58-5 Adipiplon 840486-93-3 Adoprazine 222551-17-9 Afimoxifene 68392-35-8 Aflibercept 862111-32-8 Agatolimod
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2012/0022039 A1 Schwink Et Al
    US 20120022039A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2012/0022039 A1 Schwink et al. (43) Pub. Date: Jan. 26, 2012 (54) NOVEL SUBSTITUTED INDANES, METHOD Publication Classification FOR THE PRODUCTION THEREOF, AND USE (51) Int. Cl. THEREOF AS DRUGS A 6LX 3L/397 (2006.01) C07D 207/06 (2006.01) C07D 2L/22 (2006.01) C07D 22.3/04 (2006.01) (75) Inventors: Lothar Schwink, Frankfurt am C07D 22L/22 (2006.01) Main (DE); Siegfried Stengelin, C07C 235/54 (2006.01) Frankfurt am Main (DE); Matthias C07D 307/14 (2006.01) Gossel, Frankfurt am Main (DE); A63L/35 (2006.01) Klaus Wirth, Frankfurt am Main A6II 3/40 (2006.01) (DE) A6II 3/445 (2006.01) A6II 3/55 (2006.01) A63L/439 (2006.01) A6II 3/66 (2006.01) (73) Assignee: SANOFI, Paris (FR) A6II 3/34 (2006.01) A6IP3/10 (2006.01) A6IP3/04 (2006.01) A6IP3/06 (2006.01) (21) Appl. No.: 13/201410 A6IPL/I6 (2006.01) A6IP3/00 (2006.01) C07D 309/04 (2006.01) (52) U.S. Cl. .................... 514/210.01; 549/426: 548/578; (22) PCT Filed: Feb. 12, 2010 546/205; 540/484; 546/112:564/176; 549/494; 514/459:514/408: 514/319; 514/212.01; 514/299; 514/622:514/471 (86). PCT No.: PCT/EP2010/051796 (57) ABSTRACT The invention relates to substituted indanes and derivatives S371 (c)(1), thereof, to physiologically acceptable salts and physiologi (2), (4) Date: Oct. 4, 2011 cally functional derivatives thereof, to the production thereof, to drugs containing at least one substituted indane according (30) Foreign Application Priority Data to the invention or derivative thereof, and to the use of the Substituted indanes according to the invention and to deriva Feb.
    [Show full text]
  • Potential Cannabis Antagonists for Marijuana Intoxication
    Central Journal of Pharmacology & Clinical Toxicology Bringing Excellence in Open Access Review Article *Corresponding author Matthew Kagan, M.D., Cedars-Sinai Medical Center, 8730 Alden Drive, Los Angeles, CA 90048, USA, Tel: 310- Potential Cannabis Antagonists 423-3465; Fax: 310.423.8397; Email: Matthew.Kagan@ cshs.org Submitted: 11 October 2018 for Marijuana Intoxication Accepted: 23 October 2018 William W. Ishak, Jonathan Dang, Steven Clevenger, Shaina Published: 25 October 2018 Ganjian, Samantha Cohen, and Matthew Kagan* ISSN: 2333-7079 Cedars-Sinai Medical Center, USA Copyright © 2018 Kagan et al. Abstract OPEN ACCESS Keywords Cannabis use is on the rise leading to the need to address the medical, psychosocial, • Cannabis and economic effects of cannabis intoxication. While effective agents have not yet been • Cannabinoids implemented for the treatment of acute marijuana intoxication, a number of compounds • Antagonist continue to hold promise for treatment of cannabinoid intoxication. Potential therapeutic • Marijuana agents are reviewed with advantages and side effects. Three agents appear to merit • Intoxication further inquiry; most notably Cannabidiol with some evidence of antipsychotic activity • THC and in addition Virodhamine and Tetrahydrocannabivarin with a similar mixed receptor profile. Given the results of this research, continued development of agents acting on cannabinoid receptors with and without peripheral selectivity may lead to an effective treatment for acute cannabinoid intoxication. Much work still remains to develop strategies that will interrupt and reverse the effects of acute marijuana intoxication. ABBREVIATIONS Therapeutic uses of cannabis include chronic pain, loss of appetite, spasticity, and chemotherapy-associated nausea and CBD: Cannabidiol; CBG: Cannabigerol; THCV: vomiting [8]. Recreational cannabis use is on the rise with more Tetrahydrocannabivarin; THC: Tetrahydrocannabinol states approving its use and it is viewed as no different from INTRODUCTION recreational use of alcohol or tobacco [9].
    [Show full text]
  • Potential Health Benefits of Cannabis Extracts: a Review Maria Rosana Ramirez
    International Journal of Chemical and Biomedical Science 2016; 2(1): 1-8 Published online March 1, 2016 (http://www.aascit.org/journal/ijcbs) Potential Health Benefits of Cannabis Extracts: A Review Maria Rosana Ramirez CITER-The National Scientific and Technical Research Council (CONICET), Argentine Government, Agency, Argentina Email address [email protected] Citation Maria Rosana Ramirez. Potential Health Benefits of Cannabis Extracts: A Review. International Journal of Chemical and Biomedical Science . Vol. 2, No. 1, 2016, pp. 1-8. Keywords Abstract Non-cannabinoids Compounds, A central tenet underlying the use of plant preparations is that herbs contain many Cannabis Extracts, bioactive compounds. Cannabis contains tetrahydrocannabinols (THC) a primary Bioactivity metabolite with reported psychotropic effects. Therefore, the presence of THC makes controversial the use of Cannabis to treat diseases by which their uses and applications were limited. The question then is: is it possible to use the extracts from Cannabis to treat the diseases related with it use in folk medicine? More recently, the synergistic Received: January 24, 2016 contributions of bioactive constituents have been scientifically demonstrated. We Revised: February 10, 2016 reviewed the literature concerning medical cannabis and its secondary metabolites, Accepted: February 12, 2016 including fraction and total extracts. Scientific evidence shows that secondary metabolites in cannabis may enhance the positive effects of THC a primary metabolite. Other chemical components (cannabinoid and non-cannabinoid) in cannabis or its extracts may reduce THC-induced anxiety, cholinergic deficits, and immunosuppression; which could increase its therapeutic potential. Particular attention will be placed on non- cannabinoid compounds interactions that could produce synergy with respect to treatment of pain, inflammation, epilepsy, fungal and bacterial infections.
    [Show full text]
  • The Expanded Endocannabinoid System/Endocannabinoidome As a Potential Target for Treating Diabetes Mellitus
    Current Diabetes Reports (2019) 19:117 https://doi.org/10.1007/s11892-019-1248-9 OBESITY (KM GADDE, SECTION EDITOR) The Expanded Endocannabinoid System/Endocannabinoidome as a Potential Target for Treating Diabetes Mellitus Alain Veilleux1,2,3 & Vincenzo Di Marzo1,2,3,4,5 & Cristoforo Silvestri3,4,5 # Springer Science+Business Media, LLC, part of Springer Nature 2019 Abstract Purpose of Review The endocannabinoid (eCB) system, i.e. the receptors that respond to the psychoactive component of cannabis, their endogenous ligands and the ligand metabolic enzymes, is part of a larger family of lipid signals termed the endocannabinoidome (eCBome). We summarize recent discoveries of the roles that the eCBome plays within peripheral tissues in diabetes, and how it is being targeted, in an effort to develop novel therapeutics for the treatment of this increasingly prevalent disease. Recent Findings As with the eCB system, many eCBome members regulate several physiological processes, including energy intake and storage, glucose and lipid metabolism and pancreatic health, which contribute to the development of type 2 diabetes (T2D). Preclinical studies increasingly support the notion that targeting the eCBome may beneficially affect T2D. Summary The eCBome is implicated in T2D at several levels and in a variety of tissues, making this complex lipid signaling system a potential source of many potential therapeutics for the treatments for T2D. Keywords Endocannabinoidome . Bioactive lipids . Peripheral tissues . Glucose . Insulin Introduction: The Endocannabinoid System cannabis-derived natural product, Δ9-tetrahydrocannabinol and its Subsequent Expansion (THC), responsible for most of the psychotropic, euphoric to the “Endocannabinoidome” and appetite-stimulating actions (via CB1 receptors) and immune-modulatory effects (via CB2 receptors) of marijuana, The discovery of two G protein-coupled receptors, the canna- opened the way to the identification of the endocannabinoids binoid receptor type-1 (CB1) and − 2 (CB2) [1, 2], for the (eCBs).
    [Show full text]
  • Harnessing the Endocannabinoid 2-Arachidonoylglycerol to Lower Intraocular Pressure in a Murine Model
    Glaucoma Harnessing the Endocannabinoid 2-Arachidonoylglycerol to Lower Intraocular Pressure in a Murine Model Sally Miller,1 Emma Leishman,1 Sherry Shujung Hu,2 Alhasan Elghouche,1 Laura Daily,1 Natalia Murataeva,1 Heather Bradshaw,1 and Alex Straiker1 1Department of Psychological and Brain Sciences, Indiana University, Bloomington, Indiana, United States 2Department of Psychology, National Cheng Kung University, Tainan, Taiwan Correspondence: Alex Straiker, De- PURPOSE. Cannabinoids, such as D9-THC, act through an endogenous signaling system in the partment of Psychological and Brain vertebrate eye that reduces IOP via CB1 receptors. Endogenous cannabinoid (eCB) ligand, 2- Sciences, Indiana University, Bloom- arachidonoyl glycerol (2-AG), likewise activates CB1 and is metabolized by monoacylglycerol ington, IN 47405, USA; lipase (MAGL). We investigated ocular 2-AG and its regulation by MAGL and the therapeutic [email protected]. potential of harnessing eCBs to lower IOP. Submitted: February 16, 2016 Accepted: May 16, 2016 METHODS. We tested the effect of topical application of 2-AG and MAGL blockers in normotensive mice and examined changes in eCB-related lipid species in the eyes and spinal Citation: Miller S, Leishman E, Hu SS, cord of MAGL knockout (MAGLÀ/À) mice using high performance liquid chromatography/ et al. Harnessing the endocannabinoid tandem mass spectrometry (HPLC/MS/MS). We also examined the protein distribution of 2-arachidonoylglycerol to lower intra- ocular pressure in a murine model. MAGL in the mouse anterior chamber. Invest Ophthalmol Vis Sci. RESULTS. 2-Arachidonoyl glycerol reliably lowered IOP in a CB1- and concentration-dependent 2016;57:3287–3296. DOI:10.1167/ manner. Monoacylglycerol lipase is expressed prominently in nonpigmented ciliary iovs.16-19356 epithelium.
    [Show full text]
  • Liver Disease ISSUE BRIEF on LIVER DISEASE
    Liver Disease ISSUE BRIEF ON LIVER DISEASE Introduction Briefings such as this one are prepared in response to petitions to add new conditions to the list of qualifying conditions for the Minnesota medical cannabis program. The intention of these briefings is to present to the Commissioner of Health, to members of the Medical Cannabis Review Panel, and to interested members of the public scientific studies of cannabis products as therapy for the petitioned condition. Brief information on the condition and its current treatment is provided to help give context to the studies. The primary focus is on clinical trials and observational studies, but for many conditions there are few of these. A selection of articles on pre-clinical studies (typically laboratory and animal model studies) will be included, especially if there are few clinical trials or observational studies. Though interpretation of surveys is usually difficult because it is unclear whether responders represent the population of interest and because of unknown validity of responses, when published in peer-reviewed journals surveys will be included for completeness. When found, published recommendations or opinions of national organizations medical organizations will be included. Searches for published clinical trials and observational studies are performed using the National Library of Medicine’s MEDLINE database using key words appropriate for the petitioned condition. Articles that appeared to be results of clinical trials, observational studies, or review articles of such studies, were accessed for examination. References in the articles were studied to identify additional articles that were not found on the initial search. This continued in an iterative fashion until no additional relevant articles were found.
    [Show full text]
  • 2 Spice English Presentation
    Spice Spice contains no compensatory substances Специи не содержит компенсационные вещества Spice is a mix of herbs (shredded plant material) and manmade chemicals with mind-altering effects. It is often called “synthetic marijuana” because some of the chemicals in it are similar to ones in marijuana; but its effects are sometimes very different from marijuana, and frequently much stronger. It is most often labeled “Not for Human Consumption” and disguised as incense. Eliminationprocess • The synthetic agonists such as THC is fat soluble. • Probably, they are stored as THC in cell membranes. • Some of the chemicals in Spice, however, attach to those receptors more strongly than THC, which could lead to a much stronger and more unpredictable effect. • Additionally, there are many chemicals that remain unidentified in products sold as Spice and it is therefore not clear how they may affect the user. • Moreover, these chemicals are often being changed as the makers of Spice alter them to avoid the products being illegal. • To dissolve the Spice crystals Acetone is used endocannabinoids synhtetic THC cannabinoids CB1 and CB2 agonister Binds to cannabinoidreceptor CB1 CB2 - In the brain -in the immune system Decreased avtivity in the cell ____________________ Maria Ellgren Since some of the compounds have a longer toxic effects compared to naturally THC, as reported: • negative effects that often occur the day after consumption, as a general hangover , but without nausea, mentally slow, confused, distracted, impairment of long and short term memory • Other reports mention the qualitative impairment of cognitive processes and emotional functioning, like all the oxygen leaves the brain.
    [Show full text]
  • In Silico Assessment of Drug-Like Properties of Phytocannabinoids in Cannabis Sativa
    EDUCATUM JSMT Vol. 4 No. 2 (2017) ISSN 2289-7070 / eISSN 2462-2451 (1-7) https://ejournal.upsi.edu.my/journal/EDSC In Silico Assessment of Drug-Like Properties of Phytocannabinoids in Cannabis Sativa Shakinaz Desa1*, Asiah Osman2, and Richard Hyslop3 1Department of Biology, Universiti Pendidikan Sultan Idris, Malaysia, 2Natural Product Division, Forest Research Institute Malaysia, 3Department of Chemistry and Biochemistry, University of Northern Colorado, USA *Corresponding author: [email protected] Abstract This study investigated drug-like properties of phytocannabinoids in Cannabis sativa using an in silico study. We report sixteen phytocannabinoids: cannabidiol (CBD), cannabidiolic acid (CBDA), cannabinol (CBN), cannabichromene (CBC), cannabigerol (CBG), cannabicyclol (CBL), cannabivarin (CBV), cannabidivarin (CBDV), cannabichromevarin (CBCV), cannabigerovarin (CBGV), cannabinodiol (CBDL), cannabielsoin (CBE), cannabitriol (CBT), Δ9-tetrahydrocannabinol (Δ9-THC), Δ9-tetrahydrocannabivarin (Δ9-THCV), and Δ8-tetrahydrocannabinol (Δ8-THC). All chemical structures and properties were obtained from PubChem Compound, National Center for Biotechnology Information, U.S. National Library of Medicine. Molinspiration was used for the calculation of molecular properties and bioactivity score. The parameters were molecular weight (MW), number of hydrogen acceptor (HBA), number of hydrogen donor (HBD), partition coefficient (cLogP), polar surface area (PSA) and number of rotatable bonds (NROTB). We predicted bioactivity scores for G Protein-Coupled Receptors (GPCR) ligand, ion channel modulator, kinase inhibitor, nuclear receptor ligand, protease inhibitor and enzyme inhibitor. Lipinski’s rule was used as reference to determine the drug-like properties of the phytocannabinoids. All compounds have MW<500, HBA<10, HBD<5, TPSA<140Å2 and NRTOB<10. Bioactivity score showed an active or moderately active in all compounds.
    [Show full text]
  • The Handbook of Cannabis Therapeutics: from Bench to Bedside
    Handbook of Cannabis Therapeutics From Bench to Bedside 9780789030979 Handbook of Cannabis Therapeutics From Bench to Bedside Size: 212 x 152mm Spine size: 26 mm Color pages: Binding: Paperback THE HAWORTH PRESS® Haworth Series in Integrative Healing Ethan Russo Editor The Last Sorcerer: Echoes of the Rainforest by Ethan Russo Professionalism and Ethics in Complementary and Alternative Medicine by John Crellin and Fernando Ania Cannabis and Cannabinoids: Pharmacology, Toxicology, and Therapeutic Potential by Franjo Grotenhermen and Ethan Russo Modern Psychology and Ancient Wisdom: Psychological Healing Practices from the World’s Religious Traditions edited by Sharon G. Mijares Complementary and Alternative Medicine: Clinic Design by Robert A. Roush Herbal Voices: American Herbalism Through the Words of American Herbalists by Anne K. Dougherty The Healing Power of Chinese Herbs and Medicinal Recipes by Joseph P. Hou and Youyu Jin Alternative Therapies in the Treatment of Brain Injury and Neurobehavioral Disorders: A Practical Guide edited by Gregory J. Murrey Handbook of Cannabis Therapeutics: From Bench to Bedside edited by Ethan B. Russo and Franjo Grotenhermen Handbook of Cannabis Therapeutics From Bench to Bedside Ethan B. Russo, MD Franjo Grotenhermen, MD Editors Routledge Taylor &. Francis Croup NEW YORK AND LONDON First Published by The Haworth Press, Inc., 10 Alice Street, Binghamton, NY 13904-1580. Transferred to Digital Printing 2010 by Routledge 270 Madison Ave, New York NY 10016 2 Park Square, Milton Park, Abingdon, Oxon, OX14 4RN For more information on this book or to order, visit http://www.haworthpress.com/store/product.asp?sku=5741 or call 1-800-HAWORTH (800-429-6784) in the United States and Canada or (607) 722-5857 outside the United States and Canada or contact [email protected] © 2006 by The Haworth Press, Inc.
    [Show full text]